Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 14, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions

Malignant Solid Tumors

Interventions

DRUG

Asciminib

Patients will receive asciminib 80 mg PO once daily continuously for 28-day cycles for 2 years.

Trial Locations (1)

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston